Format

Send to

Choose Destination
Int J Tuberc Lung Dis. 2012 Jun;16(6):812-6. doi: 10.5588/ijtld.11.0637. Epub 2012 Apr 9.

Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009.

Author information

1
The National Center for TB and Lung Diseases, Georgia, Tbilisi, Georgia.

Abstract

BACKGROUND:

The optimal management strategy for patients with isoniazid (INH) monoresistant forms of tuberculosis (TB) has been widely debated. The current daily 9-month regimen of rifampin, pyrazinamide and ethambutol was established based largely on trials in settings with low TB rates and low rates of drug resistance.

OBJECTIVE:

To explore the outcomes of patients with INH-monoresistant TB in the country of Georgia, a setting with both high TB rates and drug-resistant forms of the disease.

METHODS:

Retrospective record review of all patients diagnosed with smear-positive pulmonary TB resistant to either INH or INH+SM (streptomycin) in Georgia between 2007 and 2009.

RESULTS:

Of 8752 patients with pulmonary TB registered in Georgia, 909 were found to have INH or INH+SM resistance. Treatment outcomes were relatively poor in this group, with only 71% treatment success. Outcomes were significantly worse among patients with older age and a history of previous treatment.

CONCLUSIONS:

INH or INH+SM resistance in pulmonary TB patients in Georgia is common. The low rates of treatment success suggest the need for an improved treatment regimen for patients with resistance to these first-line drugs; this need is particularly pronounced among the subset of patients with a history of previous treatment.

PMID:
22507372
PMCID:
PMC3786434
DOI:
10.5588/ijtld.11.0637
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Ingenta plc Icon for PubMed Central
Loading ...
Support Center